Source:http://linkedlifedata.com/resource/pubmed/id/16817644
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2006-7-4
|
| pubmed:abstractText |
Inositol 6-phosphate (IP-6) has demonstrated novel anti-cancer activity using several different tumor models. IP-6, or phytic acid, has antioxidant properties that directly act to inhibit cancer cell growth. In previous experiments using Hep-2 cells treated with a single treatment dose of IP-6 (1 mM) showed decreases in number only after 72 hours. The goal of this experiment was to deliver IP-6 in a sustained continuous manner for periods of 24, 48 and 72 hours to Hep-2 cancer cells and compare the changes in cell growth and morphology after a single bolus dose of IP-6. Our results indicated that IP-6 administered as a bolus dose was unable to reduce Hep-2 cell numbers after 24 hours. By 48 and 72 hours an approximate 50% increase in cell numbers were seen in the single dose treatment group. Sustained delivery of IP-6 resulted in significant reduction of cells over 48 hours. The dose of IP-6 given (1 mM) did not induce changes in cellular protein concentrations nor increase cellular membrane damage. Morphologically, the Hep-2 cell appear small, round to cuboidal in shape with dark eccentric nuclei and scant cytoplasm. After treatment with 1 mM IP-6, the cells showed evidence of degeneration with irregular cell borders and hyperchromatic nuclei. Overall, 1 mM IP-6 was unable to reduce Hep-2 cell proliferation for periods greater than 48 hours; however, further evaluation of the Hep-2 cytology revealed significant cellular degenerative changes that warrant additional studies to understand the action of IP-6.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0067-8856
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
42
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
416-21
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading |
pubmed-meshheading:16817644-Antineoplastic Agents,
pubmed-meshheading:16817644-Cell Line, Tumor,
pubmed-meshheading:16817644-Cell Proliferation,
pubmed-meshheading:16817644-Cell Size,
pubmed-meshheading:16817644-Cell Survival,
pubmed-meshheading:16817644-Delayed-Action Preparations,
pubmed-meshheading:16817644-Dose-Response Relationship, Drug,
pubmed-meshheading:16817644-Humans,
pubmed-meshheading:16817644-Inositol Phosphates,
pubmed-meshheading:16817644-Laryngeal Neoplasms,
pubmed-meshheading:16817644-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Hep-2 cellular function following either a bolus administration or continuous sustained release of IP-6.
|
| pubmed:affiliation |
University of Mississippi Medical Center, Jackson, MS 39216, USA.
|
| pubmed:publicationType |
Journal Article
|